Aryl iodides
eMolecules Synthonix 2-Bromo-5-iodo-1 3-dimethylbenzene 250mg 649424016 B48771 0 000 689260-53-5 MFCD07780650 310 960 C8H8BrI
Synthonix 2-Bromo-5-iodo-1 3-dimethylbenzene 250mg 649424016 B48771 0 000 689260-53-5 MFCD07780650 310 960 C8H8BrI
eMolecules Pharmablock tert-butyl 6-iodo-2-azaspiro[3 3]heptane-2-carboxylate 500mg 713714201 PBXH381 0 000 2059140-61-1 323 174 C11H18INO2
Pharmablock tert-butyl 6-iodo-2-azaspiro[3 3]heptane-2-carboxylate 500mg 713714201 PBXH381 0 000 2059140-61-1 323 174 C11H18INO2
eMolecules Ambeed / Methyl 3-iodothiophene-2-carboxylate / 250mg / 521468718 / A425374 / / 62353-77-9 / MFCD03407485 / 268.070 / C6H5IO2S
Ambeed / Methyl 3-iodothiophene-2-carboxylate / 250mg / 521468718 / A425374 / / 62353-77-9 / MFCD03407485 / 268.070 / C6H5IO2S
Medchemexpress LLC Methylcbi-azaindole-benzamide-mom-boc-ethylenediamine-d | 2222445-87-4 | 99.7% | 859.36 | C44H51ClN6O10 | 1 MG
MethylCBI-azaindole-benzamide-MOM-Boc-ethylenediamine-D is a cleavable ADC linker used in the synthesis of antibody-drug conjugates and supplied as a high-purity research reagent for conjugation and synthetic workflows.
- Cleavable linker for intracellular release
- High purity (99.7%)
- Molecular weight 859.36 g/mol
- Available in small research quantities (1 mg and larger)
- Storage: powder at -20°C; in solvent at -80°C (6 months) or -20°C (1 month)
Apexbio Technology LLC 5-Iodo-dCTP(Synonyms: 5-Iodo-2'-deoxycytidine 5'-triphosphate, 5-Iodo-dCTP, 5-Iodo-deoxycytidine triphosphate), 50ul (100 mM).
5-Iodo-dCTP is a bioactive deoxynucleotide analog known to modulate nucleotide metabolism by interfering with specific aspects of DNA synthesis Through incorporation into nucleic acids it disrupts normal DNA replication processes allowing detailed exploration of nucleotide biosynthesis pathways Experimentally 5-Iodo-dCTP serves as a molecular tool to probe polymerase enzyme function and analyze mechanisms underlying DNA synthesis fidelity It is commonly employed in molecular biology investigations facilitating studies on disease-associated disruptions in nucleic acid metabolism
eMolecules Synthonix - Stock (3 5-Dimethylisoxazol-4-yl)methanamine 250mg 505086799 D41432 0 000 131052-47-6 MFCD06213033 126 159 C6H10N2O
Synthonix - Stock (3 5-Dimethylisoxazol-4-yl)methanamine 250mg 505086799 D41432 0 000 131052-47-6 MFCD06213033 126 159 C6H10N2O
Apexbio Technology LLC 5-Iodo-UTP(Synonyms: 5-Iodouridine triphosphate, 5-Iodo-UTP sodium salt, Iodo-UTP, 5-Iodo-uridine 5'-triphosphate), 100ul (100 mM).
5-Iodo-UTP is an iodinated derivative of uridine triphosphate (UTP) serving as a substrate in RNA synthesis and modification reactions In vitro RNA polymerases incorporate 5-Iodo-UTP into RNA transcripts enabling the production of labeled RNA probes for hybridization assays nucleic acid localization studies and analyses of RNA-protein interactions It also facilitates the investigation of RNA polymerase substrate specificity and the functional mapping of RNA molecules
eMolecules Pharmablock 3-iodo-1H 4H 5H 6H-cyclopenta[c]pyrazole 50mg 551121717 PBLJ8278 0 000 1426424-00-1 MFCD26406995 234 040 C6H7IN2
Pharmablock 3-iodo-1H 4H 5H 6H-cyclopenta[c]pyrazole 50mg 551121717 PBLJ8278 0 000 1426424-00-1 MFCD26406995 234 040 C6H7IN2
eMolecules Pharmablock tert-butyl 6-iodo-2-azaspiro[3 3]heptane-2-carboxylate 250mg 713714200 PBXH381 0 000 2059140-61-1 323 174 C11H18INO2
Pharmablock tert-butyl 6-iodo-2-azaspiro[3 3]heptane-2-carboxylate 250mg 713714200 PBXH381 0 000 2059140-61-1 323 174 C11H18INO2
Apexbio Technology LLC Nintedanib (BIBF 1120) 656247-17-5 10mM (in 1mL DMSO)
Nintedanib (BIBF 1120 CAS 656247-17-5) is an orally bioavailable small-molecule tri-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3) fibroblast growth factor receptors (FGFR1-3) and platelet-derived growth factor receptors (PDGFR / ) By inhibiting these receptor pathways at nanomolar concentrations (IC50 20 100 nmol/L) Nintedanib disrupts angiogenesis signaling and demonstrates antiangiogenic activity It is extensively investigated in preclinical and clinical research for idiopathic pulmonary fibrosis (IPF) as well as oncology including non-small-cell lung carcinoma ovarian cancer colorectal cancer and hepatocellular carcinoma